Delivery Order SPE2DE21D0005-SPE2D625F0RXU
- Not listed
- Organogenesis Inc., a regenerative medicine company based in Canton, Massachusetts, was awarded a delivery order valued at $3,400 on July 17, 2025, by the Defense Logistics Agency's Medical Supply Chain division. The delivery order, which carries a fixed-price contract type with economic price adjustment provisions, is for PURAPLY AM XT EF, a 5-layer fenestrated advanced wound care product. The contract does not utilize a set-aside designation, indicating Organogenesis competed as a standard...
- Organogenesis Inc., a regenerative medicine company headquartered in Canton, Massachusetts, was awarded a $17.82K delivery order on September 9, 2025, for PURAPLY SX 6CM x 9CM wound care dressings. This fixed-price contract with economic price adjustment carries an ultimate completion date of September 12, 2025, and is being funded through the Medical Supply Chain, a defense-oriented federal agency. The award was made on a competitive basis with no set-aside designation, reflecting...
- Organogenesis Inc., a Canton, Massachusetts-based regenerative medicine company, received a delivery order award valued at $1,239.95 from the Defense Logistics Agency's Medical Supply Chain for APLIGRAF, an advanced wound care and tissue regeneration product. The contract, awarded on May 7, 2025, carries a fixed price structure with economic price adjustment provisions and is scheduled for completion by May 12, 2025. No set-aside designation was used in this award, indicating Organogenesis...
- Organogenesis Inc., a regenerative medicine company headquartered in Canton, Massachusetts, has been awarded a delivery order by the Defense Logistics Agency (DLA) Medical Supply Chain for PURAPLY AM XT 4.91X4.91 wound care dressings. The fixed-price delivery order, valued at $11,580.00, was awarded on August 15, 2025, with an ultimate completion date of August 20, 2025. The contract carries no set-aside designation, allowing the company to compete as a standard commercial vendor. The place of...
- Organogenesis Inc. was awarded a $8,500 delivery order by the Defense Logistics Agency's Medical Supply Chain on July 23, 2025, for PURAPLY AM XT EF, a five-layer fenestrated advanced wound care product. The contract is structured as a fixed-price agreement with economic price adjustment provisions and is scheduled for completion by July 28, 2025. The work will be performed at Organogenesis' headquarters in Canton, Massachusetts. No set-aside designation was utilized for this award, indicating...
- Organogenesis Inc., a regenerative medicine company headquartered in Canton, Massachusetts, was awarded a delivery order valued at $1,239.95 for APLIGRAF, an advanced wound care and tissue regeneration product. The contract, awarded on May 30, 2025, with an ultimate completion date of June 4, 2025, utilizes fixed-price pricing with economic price adjustment terms. The award was made without a set-aside designation, indicating that Organogenesis competed as a standard commercial vendor. The...
- This federal contract award was made by the Medical Supply Chain division of the U.S. Defense Department to Organogenesis Inc., a regenerative medicine company based in Canton, Massachusetts. The $5,100 fixed-price delivery order, awarded on May 12, 2025, is for PURAPLY AM XT 4.91x4.91 wound dressings with an ultimate completion date of May 15, 2025. The contract does not utilize a set-aside designation, indicating Organogenesis competed as a standard commercial vendor. Organogenesis holds...
- Organogenesis Inc., a regenerative medicine company headquartered in Canton, Massachusetts, was awarded a delivery order valued at $2,088.00 for PURAPLY Micronized, 500mg on July 31, 2025, with an ultimate completion date of August 5, 2025. This fixed-price contract with economic price adjustment was awarded without set-aside designation by the Defense Logistics Agency's Medical Supply Chain division. PURAPLY Micronized is an advanced wound care product utilized in regenerative medicine...
- The U.S. Defense Logistics Agency (DLA) Troop Support Medical awarded a $1,118.88 fixed-price delivery order with economic price adjustment to Organogenesis Inc., a leading regenerative medicine company based in Canton, Massachusetts. The order is for PURAPLY AM (2x2) 4 SQ CM, an advanced wound care product. This order is part of Organogenesis' broader federal contract vehicles, including a $49.5 million multiple-award Indefinite Delivery Contract with DLA Troop Support Medical for wound care...
- The U.S. Defense Logistics Agency's Medical Supply Chain division awarded a $8,500 delivery order to Organogenesis Inc. on August 4, 2025, for PURAPLY AM XT EF 5-layer fenestrated wound care dressing. The contract is fixed-price with economic price adjustment and carries an ultimate completion date of August 7, 2025. The award was made without a set-aside designation, allowing Organogenesis to compete as a standard commercial vendor. Performance will take place at the company's headquarters in...
- SPE2DE21D0005Indefinite Delivery Contract
- SPE2DE21D0005-SPE2D625F0RXUDelivery Order
Organogenesis Inc., a regenerative medicine company based in Canton, Massachusetts, was awarded a delivery order valued at $5,790.00 by the Defense Logistics Agency's Medical Supply Chain on August 11, 2025, with an ultimate completion date of August 14, 2025. The contract is for PURAPLY AM XT 4.91X4.91, an advanced wound care dressing used for surgical and wound treatment applications. The award utilized fixed-price pricing with economic price adjustment provisions and was not designated as a set-aside contract, indicating Organogenesis competed as a standard commercial vendor. This delivery order is issued under one of Organogenesis's established indefinite delivery vehicles with the Defense Logistics Agency Troop Support Medical, which carries a $49.5 million multiple-award capacity running through June 2026. Organogenesis serves as a key supplier of regenerative medicine and advanced wound care products to defense and veteran healthcare systems, providing critical medical supplies to support military personnel and veterans. The company maintains a comprehensive portfolio of federal contracts with both the Defense Logistics Agency and the Department of Veterans Affairs, positioning it as a primary source for surgical biologics and tissue regeneration solutions within the government healthcare procurement landscape.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $5.8k | 8/11/25 |